GT Biopharma, Inc. is advancing a proprietary tri-specific NK cell engager platform — branded TriKE® — through two active clinical programs in 2026. The company's lead candidate is enrolling patients in a Phase 1 trial for relapsed/refractory acute myeloid leukemia today. A second Phase 1 trial in B7-H3 solid tumors is set to begin mid-2026.
This page is a presentation piece introducing you to GTBP. Review the chart, pipeline, financial snapshot and disclosure below — and conduct your own research before any investment decision.
For a company at this market capitalization, GTBP enters 2026 with what its management characterizes as a meaningful sequence of disclosed milestones: a Phase 1 trial in active dose-escalation, a second FDA-cleared IND moving toward first-patient-dosed, and disclosed cash runway through year-end. These are the disclosed catalysts to track — outcomes are not guaranteed.
The company expects to initiate dosing in Cohort 5 (25 µg/kg/day) of the ongoing Phase 1 dose-escalation study for relapsed/refractory CD33+ AML and high-risk MDS.1
The Phase 1 basket trial of GTB-5550 — the first dual-nanobody TriKE® — is on track to initiate, targeting up to seven solid tumor cohorts (prostate, ovarian, breast, head & neck, NSCLC, pancreatic, bladder).1
The next disclosed clinical update is anticipated in Q3 2026, including longer-term follow-up on Cohorts 1–3 and initial observations from Cohorts 4 and 5.1
Proforma cash balance of approximately $9 million as of January 31, 2026 is anticipated to fund operations through the fourth quarter of 2026.1
Where CAR-T therapies require expensive, time-consuming individualized cell engineering, GT Biopharma's TriKE® molecules are described by the company as small, off-the-shelf single-chain fusion proteins designed to engage Natural Killer (NK) cells — the innate immune system's resident assassins — and direct them onto tumor antigens.2
A camelid nanobody arm engages the CD16 activating receptor on Natural Killer cells, triggering antibody-dependent cellular cytotoxicity (ADCC) — the same mechanism that drives the efficacy of antibodies like rituximab.2
A wild-type human IL-15 linker sits in the middle, designed to drive NK cell proliferation, priming and survival — extending the lethal window once the NK cell is engaged.2
The third arm is the programmable part — anti-CD33 scFv for GTB-3650 (AML), anti-B7-H3 nanobody for GTB-5550 (solid tumors), anti-CD19 scFv for GTB-7550. One platform, multiple cancer types.2
The following comparison reflects GT Biopharma's positioning of TriKE® relative to autologous CAR-T therapy as described in company technology disclosures.2 It is presented for educational context — not as a claim of clinical superiority.
Live trading data, technical indicators and fundamental snapshot powered by TradingView. Use these tools as one input alongside the company's SEC filings.
Three TriKE® candidates currently disclosed across hematologic malignancies, solid tumors, and autoimmune disease. Status reflects company disclosures as of the March 2, 2026 Full Year 2025 results release.1
Pipeline status reflects publicly disclosed development stages per GT Biopharma's March 2, 2026 press release and product pipeline page. Refer to the company's SEC filings (Form 10-K) for current, authoritative trial status and material risk factors.
Selected figures from GT Biopharma's March 2, 2026 Full Year 2025 financial results release.1 Investors should consult the full Form 10-K for complete financial statements, footnotes and risk factors.
* Net loss increase year-over-year was driven almost entirely by a non-cash expense from change in fair value of additional investment rights connected to the Company's Series L Preferred Stock, per the March 2, 2026 release.
Press releases and investor updates sourced from the company's IR feed.
Free GTBP investor briefings and breaking news alerts — delivered by email, with optional SMS for time-sensitive catalysts.
Nature of this publication. This article and the page on which it appears is a sponsored investor awareness presentation. It is intended to introduce readers to NASDAQ: GTBP and prompt independent due diligence. Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
Publisher and compensation. USA News Group (USANewsGroup.com) is a digital media distribution company specializing in financial publishing. USANewsGroup.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for GT Biopharma, Inc. advertising and digital media from Creative Digital Media Group ("CDMG"). There may be 3rd parties who may have shares of GT Biopharma, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article as the basis for any investment decision. The owner/operator of MIQ does not own any shares of GT Biopharma, Inc., but reserves the right to buy and sell, and will buy and sell shares of GT Biopharma, Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we have been paid by Creative Digital Media Group, who has been paid directly by the above mentioned company. We may also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles.
Accuracy of information. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Review and approval. This communication is published on behalf of GT Biopharma, Inc., and was reviewed and approved by Creative Digital Media Group ("CDMG"). CDMG is not registered with any financial or securities regulatory authority and does not provide nor claim to provide investment advice or recommendations to readers of this release. CDMG may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Investing is inherently risky. Don't trade with money you can't afford to lose. This is neither a solicitation to buy nor an offer to sell securities. The information contained in this article does not constitute investment advice and the information contained in this article is not based on an evaluation of any investor's financial situation or risk tolerance. The information presented is intended for educational purposes only.
Forward-Looking Statements. This publication contains forward-looking information subject to risks and uncertainties. Forward-looking statements include statements regarding clinical development plans, anticipated trial timelines, regulatory pathways, cash runway, and commercial potential. Actual results may differ materially from those expressed in any forward-looking statements. Investors are referred to GT Biopharma's filings with the U.S. Securities and Exchange Commission, including the most recent Form 10-K filed March 2, 2026, for a discussion of risk factors, including (i) the Company's ability to continue as a going concern; (ii) risks related to clinical trial enrollment, design and outcomes; (iii) the need for additional capital; (iv) NASDAQ continued listing requirements; and (v) the risk that the Company's products may fail to achieve necessary safety and efficacy endpoints during clinical trials.
Sources cited (¹ ²) above: [1] GT Biopharma, Inc., "GT Biopharma Reports Full Year 2025 Financial Results," March 2, 2026 (GlobeNewswire / Company IR). [2] GT Biopharma, Inc., "Our Technologies" and "Product Pipeline — Overview," gtbiopharma.com. TriKE® is a registered trademark of GT Biopharma, Inc.